Direct all media inquires to the Office of Communications and Government Relations301-402-1663 email@example.com
The NIAID VTEUs have played a key role in the Institute’s effort to develop new and improved vaccines and therapies against infectious diseases for over four decades. They have conducted hundreds of clinical trials, many of which have contributed to vaccine licensure. An important strength of the VTEUs is their ability to enroll large numbers of volunteers into trials rapidly and vaccinate them in a safe, effective and quick manner. This rapid-response capability is especially important for testing vaccines designed to counteract emerging public health concerns, such as the ongoing pandemic of 2009 H1N1 influenza.
Statement: Early Results from Clinical Trials of 2009 H1N1 Influenza Vaccines in Healthy Adults—Sept. 11, 2009
Q&A: NIAID Trial of Candidate 2009 H1N1 Influenza Vaccine in Pregnant Women at the Vaccine and Treatment Evaluation Units—Sept. 9, 2009
NIAID Launches 2009 H1N1 Influenza Vaccine Trial in Pregnant Women—Sept. 9, 2009
Q&A: Pediatric Trials of Candidate 2009 H1N1 Vaccine at NIAID Vaccine and Treatment Evaluation Units (VTEUs)—Aug. 19, 2009
NIAID to Begin Trials of Candidate H1N1 Vaccines in Children—Aug. 18, 2009
Last Updated April 01, 2010